Ultragenyx Pharmaceutical Inc (RARE) Expected to Post Quarterly Sales of $9.94 Million

Wall Street brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $9.94 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $4.91 million to $18.92 million. Ultragenyx Pharmaceutical reported sales of $200,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 4,870%. The company is expected to report its next earnings report on Thursday, November 1st.

On average, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $46.08 million for the current financial year, with estimates ranging from $25.22 million to $72.18 million. For the next financial year, analysts anticipate that the business will post sales of $101.60 million, with estimates ranging from $74.10 million to $144.81 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. The company had revenue of $12.79 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same quarter in the previous year, the business posted ($1.72) EPS.

RARE has been the subject of several recent research reports. Morgan Stanley reissued an “equal weight” rating and issued a $92.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday, September 10th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Barclays reissued an “overweight” rating and issued a $92.00 price target (up previously from $74.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. Robert W. Baird reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. Finally, SunTrust Banks boosted their price target on Ultragenyx Pharmaceutical to $83.00 and gave the company a “positive” rating in a research note on Monday, August 20th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.53.

In other Ultragenyx Pharmaceutical news, Director William Aliski sold 3,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $76.66, for a total transaction of $287,475.00. Following the completion of the sale, the director now owns 72,610 shares of the company’s stock, valued at $5,566,282.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total value of $603,469.00. Following the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. Insiders have sold 15,450 shares of company stock valued at $1,283,594 in the last ninety days. Company insiders own 8.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Advisors Asset Management Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $181,000. Hsbc Holdings PLC acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth approximately $213,000. JBF Capital Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $384,000. Strs Ohio lifted its holdings in shares of Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 4,300 shares during the last quarter. Finally, Pier 88 Investment Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $446,000. 96.09% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ RARE traded up $0.56 during trading hours on Wednesday, hitting $74.73. The stock had a trading volume of 518,500 shares, compared to its average volume of 520,149. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -9.99 and a beta of 1.95. Ultragenyx Pharmaceutical has a 52 week low of $41.67 and a 52 week high of $90.98.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply